FBXW7 attenuates tumor drug resistance and enhances the efficacy of immunotherapy

被引：7
|
作者：
Chen, Shimin [1 ,2 ,3 ]
Lin, Jichun [1 ,2 ,3 ]
Zhao, Jiaojiao [1 ,2 ,3 ]
Lin, Qian [1 ]
Liu, Jia [4 ]
Wang, Qiang [5 ]
Mui, Ryan [6 ]
Ma, Leina [1 ,2 ]
机构：
[1] Qingdao Univ, Canc Inst, Dept Oncol, Affiliated Hosp, Qingdao, Peoples R China
[2] Qingdao Canc Inst, Qingdao, Peoples R China
[3] Qingdao Univ, Sch Basic Med, Qingdao, Peoples R China
[4] Qingdao Univ, Sch Pharm, Dept Pharmacol, Qingdao, Peoples R China
[5] Shandong Second Prov Gen Hosp, Oncol Dept, Jinan, Peoples R China
[6] Sparrow Hosp, Dept Gastroenterol, Lansing, MI USA
来源：
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
基金：
中国国家自然科学基金;
关键词：
FBXW7; drug resistance; E3; ligase; cancer; immunotherapy; F-BOX PROTEINS; GASTRIC-CANCER; MESENCHYMAL TRANSITION; PROMOTES PROLIFERATION; CHEMO-RESISTANCE; CYCLIN-E; C-MYC; FBW7; DEGRADATION; EXPRESSION;
D O I：
10.3389/fonc.2023.1147239
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FBXW7 (F-box and WD repeat domain containing 7) is a critical subunit of the Skp1-Cullin1-F-box protein (SCF), acting as an E3 ubiquitin ligase by ubiquitinating targeted protein. Through degradation of its substrates, FBXW7 plays a pivotal role in drug resistance in tumor cells and shows the potential to rescue the sensitivity of cancer cells to drug treatment. This explains why patients with higher FBXW7 levels exhibit higher survival times and more favorable prognosis. Furthermore, FBXW7 has been demonstrated to enhance the efficacy of immunotherapy by targeting the degradation of specific proteins, as compared to the inactivated form of FBXW7. Additionally, other F-box proteins have also shown the ability to conquer drug resistance in certain cancers. Overall, this review aims to explore the function of FBXW7 and its specific effects on drug resistance in cancer cells.
引用
收藏
页数：14
相关论文
共 50 条
  • [21] miR-367 promotes tumor growth by inhibiting FBXW7 in NSCLC
    Xiao, Guodong
    Gao, Xiao
    Sun, Xin
    Yang, Chengcheng
    Zhang, Boxiang
    Sun, Ruiying
    Huang, Guanghong
    Li, Xiang
    Liu, Jian
    Du, Ning
    Liu, Dapeng
    Liang, Rui
    Ren, Hong
    Qin, Sida
    ONCOLOGY REPORTS, 2017, 38 (02) : 1190 - 1198
  • [22] Prevention of cancer dormancy by Fbxw7 ablation eradicates disseminated tumor cells
    Shimizu, Hideyuki
    Takeishi, Shoichiro
    Nakatsumi, Hirokazu
    Nakayama, Keiichi I.
    JCI INSIGHT, 2019, 4 (04)
  • [23] Tumor Suppressor FBXW7 and Its Regulation of DNA Damage Response and Repair
    Lan, Huiyin
    Sun, Yi
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [24] FBXW7/hCDC4 is a general tumor suppressor in human cancer
    Akhoondi, Shahab
    Sun, Dahui
    von der Lehr, Natalie
    Apostolidou, Sophia
    Klotz, Kathleen
    Maljukova, Alena
    Cepeda, Diana
    Fiegl, Heidi
    Dofou, Dimitra
    Marth, Christian
    Mueller-Holzner, Elisabeth
    Corcoran, Martin
    Dagnell, Markus
    Nejad, Sepideh Zabihi
    Nayer, Babak Noori
    Zali, Mohammad Reza
    Hansson, Johan
    Egyhazi, Susanne
    Petersson, Fredrik
    Sangfelt, Per
    Nordgren, Hans
    Grander, Dan
    Reed, Steven I.
    Widschwendter, Martin
    Sangfelt, Olle
    Spruck, Charles
    CANCER RESEARCH, 2007, 67 (19) : 9006 - 9012
  • [25] FBXW7 Acts as an Independent Prognostic Marker and Inhibits Tumor Growth in Human Osteosarcoma
    Li, Zhanchun
    Xiao, Jie
    Hu, Kongzu
    Wang, Gang
    Li, Maoqiang
    Zhang, Jidong
    Cheng, Guangqi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (02) : 2294 - 2306
  • [26] Loss of Fbxw7 impairs development of and induces tumor formation in the mouse mammary gland
    Onoyama, Ichiro
    Kato, Kiyoko
    Nakayama, Keiichi I.
    CANCER SCIENCE, 2021, 112 : 606 - 606
  • [27] FBXW7 tumor suppressor regulation by dualspecificity tyrosine-regulated kinase 2
    Rafael Jiménez-Izquierdo
    Rosario Morrugares
    Lucía Suanes-Cobos
    Alejandro Correa-Sáez
    Martín Garrido-Rodríguez
    Laura Cerero-Tejero
    Omar M. Khan
    Susana de la Luna
    Rocío Sancho
    Marco A. Calzado
    Cell Death & Disease, 14
  • [28] FBXW7 tumor suppressor regulation by dualspecificity tyrosine-regulated kinase 2
    Jimenez-Izquierdo, Rafael
    Morrugares, Rosario
    Suanes-Cobos, Lucia
    Correa-Saez, Alejandro
    Garrido-Rodriguez, Martin
    Cerero-Tejero, Laura
    Khan, Omar M.
    de la Luna, Susana
    Sancho, Rocio
    Calzado, Marco A.
    CELL DEATH & DISEASE, 2023, 14 (03)
  • [29] Recurrent mutations in tumor suppressor FBXW7 bypass Wnt/β-catenin addiction in cancer
    Zhong, Zheng
    Virshup, David M.
    SCIENCE ADVANCES, 2024, 10 (14)
  • [30] Germline variants in tumor suppressor FBXW7 lead to impaired ubiquitination and a neurodevelopmental syndrome
    Stephenson, Sarah E. M.
    Costain, Gregory
    Blok, Laura E. R.
    Silk, Michael A.
    Nguyen, Thanh Binh
    Dong, Xiaomin
    Alhuzaimi, Dana E.
    Dowling, James J.
    Walker, Susan
    Amburgey, Kimberly
    Hayeems, Robin Z.
    Rodan, Lance H.
    Schwartz, Marc A.
    Picker, Jonathan
    Lynch, Sally A.
    Gupta, Aditi
    Rasmussen, Kristen J.
    Schimmenti, Lisa A.
    Klee, Eric W.
    Niu, Zhiyv
    Agre, Katherine E.
    Chilton, Ilana
    Chung, Wendy K.
    Revah-Politi, Anya
    Au, P. Y. Billie
    Griffith, Christopher
    Racobaldo, Melissa
    Raas-Rothschild, Annick
    Ben Zeev, Bruria
    Barel, Ortal
    Moutton, Sebastien
    Morice-Picard, Fanny
    Carmignac, Virginie
    Cornaton, Jenny
    Marle, Nathalie
    Devinsky, Orrin
    Stimach, Chandler
    Wechsler, Stephanie Burns
    Hainline, Bryan E.
    Sapp, Katie
    Willems, Marjolaine
    Bruel, Angeline
    Dias, Kerith-Rae
    Evans, Carey-Anne
    Roscioli, Tony
    Sachdev, Rani
    Temple, Suzanna E. L.
    Zhu, Ying
    Baker, Joshua J.
    Scheffer, Ingrid E.
    AMERICAN JOURNAL OF HUMAN GENETICS, 2022, 109 (04) : 601 - 617
12345